FINWIRES · TerminalLIVE
FINWIRES

瑞士股市指數上漲;愛爾康、羅技股價下跌

By

-- 週三,瑞士股市指數收漲1.77%,繼續維持上漲勢頭,因為人們對中東戰爭即將結束的希望重燃。 根據包括Axios和路透社在內的多家媒體引述消息人士報道,美國和伊朗據稱即將就一份僅有14條內容的諒解備忘錄達成協議,以結束這場戰爭。與此同時,美國總統川普在Truth Social平台上發文稱,如果伊朗“同意交出已達成協議的物品”,戰爭和封鎖將會結束。他還警告說,如果雙方未能達成協議,轟炸的規模和強度將「遠超以往」。 在瑞士國內,4月瑞士私部門狀況改善,KOF商業情勢指標從上月的16.6升至18.3。 瑞士經濟研究所KOF表示:「製造業商業景氣指標已從3月份的下滑中全面恢復。計畫工程業的指標上升幅度更大,批發貿易業的指標上升幅度則較為溫和。其他服務業和零售業也呈現溫和回升的態勢。」該研究所還指出:「然而,未來六個月的商業前景總體上趨於批發,尤其是在製造業、業度和貿易業。 企業方面,羅技國際(LOGN.SW)2026財年淨利年增至7.112億美元,高於去年同期的6.315億美元;淨銷售額也從45.5億美元增至48.4億美元。這家瑞士電腦週邊和軟體公司的股價在交易日結束時下跌了0.40%。 瑞士眼科護理產品集團愛爾康(Alcon,股票代號:ALC.SW)股價收盤下跌10.96%,原因是其第一季淨利年增率大幅下滑,從3.5億美元降至1.89億美元。營業利潤下降38%至2.92億美元,主要受效率提升計畫相關成本、無形資產減損支出、新增關稅的影響。另一方面,淨銷售額同期有所成長。 AlphaValue/Baader Europe的分析師在一份報告中指出:「儘管愛爾康在其目標市場佔據主導地位,但其投資前景取決於利潤率的提升,而利潤率的提升存在執行風險。眼科市場的增長雖然在一定程度上具有粘性,但仍被限制在個位數百分比左右。因此,我們預計愛爾康將在未來幾個季度/幾年內尋求非內生性增長“雖然目前愛爾康的股價有 12% 的上漲空間,但為了獲得更豐厚的回報,投資者或許應該等待股價進一步回調。”

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL
瑞士股市指數上漲;愛爾康、羅技股價下跌 | FINWIRES